PMID: 8587147Oct 1, 1995Paper

Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling

Journal of Veterinary Pharmacology and Therapeutics
M F LandoniP Lees

Abstract

The pharmacokinetics (PK) and pharmacodynamics (PD) of ketoprofen (KTP) were studied in calves following intravenous administration of the drug racemate at a dose rate of 3 mg/kg. To evaluate the anti-inflammatory properties of KTP, a model of acute inflammation, consisting of surgically implanted subcutaneous tissue cages stimulated by intracaveal injection of carrageenan, was used. No differences were observed between disposition curves of KTP enantiomers in plasma, exudate or transudate. This indicates that in calves KTP pharmacokinetics is not enantioselective. S(+)- and R(-)- KTP each had a short elimination half-life (t1/2 beta) of 0.42 +/- 0.08 h and 0.42 +/- 0.09 h, respectively. The volume of distribution (Vd) was low, values of 0.20 +/- 0.06 L/kg and 0.22 +/- 0.06 L/kg being obtained for R(-) and S(+)KTP, respectively. Body clearance (ClB) was high, correlating with the short elimination half-life, 0.33 +/- 0.03 L/kg/h [R(-)KTP] and 0.32 +/- 0.04 L/kg/h [S(+)-KTP]. KTP pharmacodynamics was evaluated by determining the effects on serum thromboxane (TxB2), exudate prostaglandin (PGE2), leukotriene (LTB4) and beta-glucuronidase (beta-glu) and bradykinin (BK)-induced oedematous swelling. Effect-concentration inter-relatio...Continue Reading

References

Feb 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·B E DahlströmA J Agren
Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Mar 1, 1979·Computer Programs in Biomedicine·D Z D'Argenio, A Schumitzky
Oct 1, 1992·Journal of Clinical Pharmacology·K BruneS Menzel-Soglowek
Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·W L XieD L Simmons
Oct 1, 1989·Journal of Pharmaceutical Sciences·R T FosterA S Russell
Dec 1, 1988·British Journal of Clinical Pharmacology·B C SallustioP J Meffin
Jan 1, 1988·Journal of Pharmaceutical Sciences·R T FosterS R Alballa
Oct 1, 1986·Medicinal Research Reviews·E J Ariëns
Jun 1, 1984·Clinical Pharmacology and Therapeutics·E Fuseau, L B Sheiner
Jan 1, 1982·Pharmacology & Therapeutics·N H Holford, L B Sheiner
May 1, 1982·Clinical Pharmacokinetics·T M LuddenM S Lin
Mar 1, 1993·Trends in Neurosciences·A Dray, M Perkins
Jan 1, 1994·Research in Veterinary Science·N Y ShpigelF Longo
Sep 1, 1993·Journal of Veterinary Pharmacology and Therapeutics·P JaussaudP Delatour
Jan 1, 1993·Agents and Actions. Supplements·K M HargreavesJ Q Swift
Mar 1, 1993·British Journal of Clinical Pharmacology·M VillanuevaK Schrör
Jul 1, 1996·Research in Veterinary Science·M F LandoniP Lees

❮ Previous
Next ❯

Citations

Jan 1, 1996·Veterinary Research Communications·Z ChengP Lees
Mar 1, 1996·The British Veterinary Journal·P LeesD Baggot
Mar 6, 2003·The Veterinary Journal·P LeesC Waters
Feb 8, 2003·The Veterinary Journal·Peter Lees
May 2, 1998·The Veterinary Journal·M B da SilvaP Lekeux
Jul 10, 2001·Journal of Veterinary Pharmacology and Therapeutics·C B NavarreD G Pugh
Jun 26, 2002·Journal of Veterinary Pharmacology and Therapeutics·F Shojaee Aliabadi, P Lees
Sep 6, 2002·Journal of Veterinary Pharmacology and Therapeutics·A K Arifah, P Lees
Feb 1, 1996·Journal of Veterinary Pharmacology and Therapeutics·M F Landoni, P Lees
Dec 1, 1996·Journal of Veterinary Pharmacology and Therapeutics·M F Landoni, P Lees
Sep 1, 1996·Zentralblatt für Veterinärmedizin. Reihe A·M OukessouM Alvinerie
Nov 10, 2000·The Journal of Small Animal Practice·L S Slingsby, A E Waterman-Pearson
Jan 3, 2008·American Journal of Veterinary Research·Marja R RaekallioOuti M Vainio
Jan 1, 2003·Research in Veterinary Science·P SidhuP Lees
Oct 22, 2010·Research in Veterinary Science·E NeirinckxC Vervaet
Dec 17, 2004·Journal of Veterinary Pharmacology and Therapeutics·P LeesP L Toutain
Apr 2, 2003·Journal of Veterinary Pharmacology and Therapeutics·A K ArifahP Lees
Sep 7, 2007·Journal of Veterinary Pharmacology and Therapeutics·R NagillaW R Ravis
Jan 24, 2009·Journal of Veterinary Pharmacology and Therapeutics·J M GiraudelP-L Toutain
Mar 15, 2011·Journal of Veterinary Pharmacology and Therapeutics·T K FosseB Ranheim
Mar 22, 2014·Drug Development Research·José Carlos Aguilar-CarrascoFrancisco Javier Flores-Murrieta
Nov 21, 2014·Journal of Veterinary Pharmacology and Therapeutics·E PlessersS Croubels
Jan 24, 2009·Journal of Dairy Science·A HeinrichS T Millman
Jan 29, 2000·Journal of Veterinary Pharmacology and Therapeutics·M F LandoniP Lees
Sep 26, 2000·Journal of Dairy Science·P M Faulkner, D M Weary
Jun 19, 2010·Journal of Veterinary Pharmacology and Therapeutics·M Martinez, S Modric
Aug 23, 2005·British Journal of Pharmacology·Jerome M GiraudelPierre-Louis Toutain
Feb 24, 2001·American Journal of Veterinary Research·A K ArifahP Lees
Jun 14, 2002·American Journal of Veterinary Research·Zhangrui ChengQuintin A McKellar
May 2, 2019·The Veterinary Record·Alexandra SchoosDominiek Gd Maes
Jul 16, 2002·Equine Veterinary Journal·P Lees, F Shojaee Aliabadi
Jun 1, 1997·The Veterinary Quarterly·P AnfossiS Carli

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved